Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma
A comprehensive literature review and subsequent meta-analysis of the rates of erectile dysfunction associated with the treatments of localized prostate carcinoma was conducted. A simple logistic regression analysis was used to combine the data from the 54 articles that met the selection criteria. As noted below the odds or remaining potent are noted below:

prostate_impotence_summary_robinson.gif (12293 bytes)

 
In the large literature review noted below, the incidence of erectile dysfunction (impotence or ED) varied considerably whether treatment was external beam (EBT) or seed implants (brachytherapy or BT) or surgery (radical prostatectomy or RP.)

Sexual (dys)function after radiotherapy for prostate cancer: a review
Luca Incrocci. International Journal of Radiation Oncology*Biology*Physics,2002; 52:3 : 681-693

Incidence of erectile dysfunction after EBT for prostate cancer
In the 1980s, linear accelerators were routinely used to deliver megavolt energies, and interstitial techniques were introduced. Comorbidity was seldom reported, with a few exceptions, ED rates ranged from 11 to 73%. In the 1990's Postradiation ED rates varied from 17 to 84% and, with regard to 3D-CRT, from 27 to 49%. Prospective studies in the 1990's Although these prospective studies were conducted adequately, rates of ED still varied considerably, from 7 to 72% .

Incidence of erectile dysfunction after brachytherapy for prostate cancer
In studies from the 1970s rates of ED ranged from 0 to 25%, being highest when BT was used in combination with EBT. In the 1990s, advances in radioisotope development (with the introduction of Pd-103), the emergence of sophisticated 3D computer-assisted dosimetry, intraoperative transrectal ultrasound (TRUS) availability, and introduction of the transperineal approach produced a more homogeneous and reproducible implant than had previously been possible. In general, in studies using I-125, Pd-103 or both, the ED rates ranged from 2 to 51% with the highest percentages again found when BT and EBT were combined . The highest ED rates, ranging from 25 to 89%, have been reported in studies combining a temporary Ir-192 implant with subsequent ERT. With respect to the differences between I-125 and Pd-103 BT, ED rates were 6–21% and 15% , respectively.   Some studies reported the exact time of impotence evaluation after the administration of I-125 or Pd-103 without ERT; ED rates were 2–8% at 12 months, 6–21% at 24 months, and 19% at 36 months.

The ability to achieve and sustain erections is only one component of sexuality. Loss of libido and ejaculation disorders are very important as well. A deterioration of sexual activity has been associated with the severity of ejaculatory dysfunction, particularly a decrease in volume or an absence of semen . Ejaculatory disturbances in BT studies varied from a reduction or absence of ejaculate volume (7–45%) to discomfort during ejaculation (3–11%) and hemospermia (5%)

After EBT, a lack of ejaculation was reported in 2 to 56% of patients Dissatisfaction with sex life was reported in 25–60% decreased libido in 8–53% and decreased sexual desire in 12–58% One study reported a decreased intensity of orgasm, decreased frequency and rigidity of erections, and decreased importance of sex

Comparisons between EBT and radical prostatectomy
Because of the growing popularity of 3D-CRT techniques in the 1990s, complications of ERT and RP were compared.In comparative studies, ED rates after RP varied from 48 to 98%, whereas after ERT these rates were 31–85%. A meta-analysis  involving only men potent before treatment showed that the probability of maintaining normal erections was 0.69 after ERT and 0.42 after RP. Potosky  reported on a large cohort of 1591 patients with localized PC who received RP or ERT. After 2 years of treatment, men receiving RP were more likely than men receiving ERT to be impotent (80% vs. 61%, p < 0.001). In some recently published series on ED after RP, rates of ED varied from 60 to 68% at 18 months after treatment